Analysts Positive On BioLineRx Ltd. Following Ph2 Testing Expansion For AML

On May 4, BioLineRx announced the expansion stage of the Phase 2 clinical trial for BL-8040, a drug for acute myeloid leukemia, or AML. Top-line results will be announced in the fourth quarter of this year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.